Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
- DOI
- 10.1186/s13045-026-01837-z
- Published
- 2026 Aug 10
- Container
- Journal of hematology & oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13045-026-01837-z,
title = {Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.},
author = {Mahadevan D and Barve M and Mahalingam D and Parekh J and Kurman M and Strauss J and Tremaine L and Hromas R and Sills J and McCulloch J and Harkey J and Suberg S and Zimmerman L and Zheng G and Zhou D},
year = {2026},
journal = {Journal of hematology \& oncology},
doi = {10.1186/s13045-026-01837-z},
url = {https://doi.org/10.1186/s13045-026-01837-z}
}RIS
TY - JOUR TI - Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. AU - Mahadevan D AU - Barve M AU - Mahalingam D AU - Parekh J AU - Kurman M AU - Strauss J AU - Tremaine L AU - Hromas R AU - Sills J AU - McCulloch J AU - Harkey J AU - Suberg S AU - Zimmerman L AU - Zheng G AU - Zhou D PY - 2026 JO - Journal of hematology & oncology DO - 10.1186/s13045-026-01837-z UR - https://doi.org/10.1186/s13045-026-01837-z ER -
APA
D, M., M, B., D, M., J, P., M, K., J, S., L, T., R, H., J, S., J, M., J, H., S, S., L, Z., G, Z., & D, Z. (2026). Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.. Journal of hematology & oncology. https://doi.org/10.1186/s13045-026-01837-z
Source records
- pubmed · retrieved 2026-09-26T03:14:35.813Z